Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 3—March 2023
Dispatch

Tuberculosis Preventive Therapy among Persons Living with HIV, Uganda, 2016–2022

Deus LukoyeComments to Author , Gail Gustavson, Proscovia M. Namuwenge, Simon Muchuro, Estella Birabwa, Seyoum Dejene, Julius Ssempiira, Julius N. Kalamya, Steven Baveewo, Odile Ferroussier-Davis, Lisa A. Mills, Emilio Dirlikov, Lisa J. Nelson, and Stavia Turyahabwe
Author affiliations: US Centers for Disease Control and Prevention, Kampala, Uganda (D. Lukoye, G. Gustavson, J. Ssempiira, J.N. Kalamya, S. Baveewo, L.A. Mills, E. Dirlikov, L.J. Nelson); Uganda Ministry of Health, Kampala (P.M. Namuwenge, S. Muchuro, S. Turyahabwe); US Department of Defense, Kampala (E. Birabwa); US Agency for International Development, Kampala (S. Dejene); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (O. Ferroussier-Davis)

Main Article

Table 1

Tuberculosis preventive therapy completion and coverage among persons living with HIV who received antiretroviral therapy during semiannual periods, Uganda, October 2016–March 2022*

Semiannual periods Initiated TPT Completed TPT Receiving ART† TPT eligible‡ Cumulative completion Completion rate, %§ TPT coverage, %¶
2016 Oct–2017 Mar 18,394 5,264 890,938 846,391 5,264 28.6 0.6 (5,264/846,391)
2017 Apr–2017Sep 17,391 12,360 993,070 943,417 17,624 71.1 1.9 (17,624/943,417)
2017 Oct–2018 Mar 8,162 5,188 1,030,756 979,218 22,812 63.6 2.3 (22,812/979,218)
2018 Apr–2018 Sep 18,836 13,272 1,101,716 1,046,630 36,084 70.5 3.4 (36,084/1,046,630)
2018 Oct–2019 Mar 99,602 85,954 1,097,366 1,042,498 122,038 86.3 11.7 (122,038/1,042,498)
2019 Apr–2019 Sep 443,900 391,514 1,148,258 1,090,845 513,552 88.2 47.1 (513,552/1,090,845)
2019 Oct–2020 Mar 111,898 98,399 1,201,166 1,141,108 611,951 87.9 53.6 (611,951/1,141,108)
2020 Apr–2020 Sep 172,862 158,546 1,218,006 1,157,106 770,497 91.7 66.6 (770,497/1,157,106)
2020 Oct–2021 Mar 122,969 113,296 1,239,829 1,177,838 883,793 92.1 79.1 (883,793/1,117,838)
2021 Apr–2021 Sep 134,387 124,525 1,266,588 1,203,259 1,008,318 92.7 83.8 (1,008,318/1,203,259)
2021 Oct–2022 Mar 79,949 75,173 1,283,662 1,219,479 1,083,491 94.0 88.8 (1,083,491/1,219,479)

*Patients received ART at PEPFAR-supported facilities. ART, antiretroviral therapy; PEPFAR, US President’s Emergency Plan for AIDS Relief; TPT, tuberculosis preventive therapy. †Number of adults and children receiving ART was reported quarterly; we used the number reported during the final quarter of each 6-month period. ‡TPT eligible was defined as 95% of total persons living with HIV who were receiving ART; TPT ineligibility (5%) accounts for PLHIV with active TB disease and PLHIV discontinuing TPT because of loss to follow-up, death, or adverse events. §Number of patients who completed TPT divided by the number of patients who initiated TPT × 100. ¶TPT coverage was calculated as cumulative number of persons living with HIV who completed TPT divided by the number of TPT eligible patients ´ 100.

Main Article

Page created: January 13, 2023
Page updated: February 20, 2023
Page reviewed: February 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external